Felix Klingler
Dr. med.
Felix Klingler
  • Medical specialist
  • Medical Specialist in Internal Medicine and Hematology and Oncology
  • Additional designation: Hemostasiology
Working area

Contact

Location

O24
Languages
German (Mother tongue)
English

Areas of expertise

Publications

Zurück
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2018
Vor

IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
Horns J, Beder T, Künstner A, Barz M, Bendig S, Bozzetti C, Chitadze G, Darzentas N, Iben K, Kotrova M, Martín-Subero J, Mondal M, Neumann M, Fernandez Perez R, Ströh A, Weßels W, Lenk L, Velten L, Böll B, Braitsch K, Bücklein V, Duell J, Faul C, Fiedler W, Hanoun M, Janjetovic S, Klingler F, Knop S, Röllig C, Schwartz S, Spriewald B, Steffen B, Wethmar K, Busch H, Gökbuget N, Baldus C, Bastian L, Brüggemann M
BLOOD. 2026;148(7):856-866.

Therapeutic Drug Monitoring of Arsenic Trioxide in a Patient with High-risk Acute Promyelocytic Leukemia and Hemodialysis
Klingler F, Michalowski N, Bokemeyer C, Wichmann D, Westendorf F
ONCOL RES TREAT. 2026;49(Suppl 2):123-124.

SHORTER TREATMENT, FASTER DISCHARGE. THE IMPACT OF DAY 14 ASSESSMENT IN AML PATIENTS ON AZA-VEN: A SINGLE CENTER EXPERIENCE.
Klingler F, Seubert E, Wienecke C, Pfaff S, Holzapfel A, Kruse F, Bokemeyer C, Stübig T, Fiedler W, Westendorf F
HEMASPHERE. 2026;2026(10):.

Circulating Tumor Cells and Thromboembolic Events in Patients with Glioblastoma
Rolling C, Mohme M, Bokemeyer C, Westphal M, Riethdorf S, Lamszus K, Pantel K, Klingler F, Langer F
HAMOSTASEOLOGIE. 2026;46(2):101-105.

REAL-WORLD INSIGHTS INTO SALVAGE CHEMOTHERAPY FOR FIT FAVORABLE-RISK AML PATIENTS AT FIRST RELAPSE
Seubert E, Klingler F, Ayuk F, Bokemeyer C, Fiedler W, Westendorf F
HEMASPHERE. 2026.

Plasma exchange for hyperammonemia-induced reduced consciousness after PEG-asparaginase in an adult patient with acute lymphoblastic leukemia
Klingler F, Forstreuter A, Stegat L, Kämereit S, Ullrich F, Udonta F, Krebs C, Wichmann D, Bokemeyer C, Goekbuget N, Fiedler W, Modemann F
HAEMATOLOGICA. 2025;110(7):1660-1664.

Osteonecrosis risk in adult ALL: Insights from real-world clinical laboratory data in eighty-seven patients treated with peg-asparaginase
Klingler F, Gökbuget N, Bokemeyer C, Fiedler W, Westendorf F
BLOOD. 2025;146(Supplement 1):3322-3323.

Osteonekrose bei Erwachsenen mit akuter lymphatischer Leukämie: Ein klinischer Workflow zur frühzeitigen Identifikation von Hochrisikopatienten zur Sicherstellung einer rechtzeitigen Diagnose und Intervention
Klingler F, Gökbuget N, Bokemeyer C, Fiedler W, Westendorf F
ONCOL RES TREAT. 2025;2025(48):.

Osteonecrosis as a side effect of a pediatric-based treatment regimen in adult acute lymphoblastic leukemia patients
Klingler F, Rahlwes C, Bokemeyer C, Gökbuget N, Fiedler W, Modemann F
HEMASPHERE. 2025;9(S1):115-116.

A diagnostic pitfall: Therapy-related acute promyelocytic leukemia mimicking mixed-phenotype acute leukemia
Seubert E, Ullrich F, Kruppa M, Küster L, Schaefers C, Klingler F, Bokemeyer C, Fiedler W, Stübig T, Westendorf F
BLOOD. 2025;146(Supplement 1):6936-6936.

Outcome of critically ill patients receiving systemic chemotherapy on the intensive care unit
Karagiannis P, Klingler F, Arelin V, Alsdorf W, König C, Roedl K, Fiedler W, Weisel K, Kluge S, Bokemeyer C, Wichmann D
FRONT ONCOL. 2024;14:1508112.

Regulation of coagulation activation in newly diagnosed AML by the heme enzyme myeloperoxidase
Langer F, Quick H, Beitzen-Heineke A, Janjetovic S, Mäder J, Lehr C, Bokemeyer C, Kuta P, Renné T, Fiedler W, Beckmann L, Klingler F, Rolling C
THROMB RES. 2023;229:155-163.

Inhibition of protein disulfide isomerase with PACMA-31 regulates monocyte tissue factor through transcriptional and posttranscriptional mechanisms
Beckmann L, Mäder J, Voigtlaender M, Klingler F, Schulenkorf A, Lehr C, Regenhardt J, Bokemeyer C, Ruf W, Rolling C, Langer F
THROMB RES. 2022;220:48-59.

Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine
Klingler F, Alsdorf W, Ghandili S, Wolschke C, Brauneck F, Bokemeyer C, Fiedler W, Modemann F, Karagiannis P
LEUKEMIA LYMPHOMA. 2022;63(11):2645-2651.

Bacitracin and Rutin Regulate Tissue Factor Production in Inflammatory Monocytes and Acute Myeloid Leukemia Blasts
Beckmann L, Rolling C, Voigtländer M, Mäder J, Klingler F, Schulenkorf A, Lehr C, Bokemeyer C, Ruf W, Langer F
CANCERS. 2021;13(16):3941.

Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option
Stamm H, Klingler F, Grossjohann E, Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G, Latuske E, Bokemeyer C, Kischel R, Dos Santos C, Stienen S, Friedrich M, Lutteropp M, Nagorsen D, Wellbrock J, Fiedler W
ONCOGENE. 2018;37(39):5269-5280.

Letzte Aktualisierung aus dem FIS: 19.11.2026 - 05:29 Uhr